Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.51 |
| ▸ | PPME1 | Q9Y570 | 1/20 | 0.47 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.46 |
| ▸ | ACLY | P53396 | 2/20 | 0.45 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.45 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.44 |
| ▸ | CTSG | P08311 | 1/20 | 0.44 |
| ▸ | CMA1 | P23946 | 1/20 | 0.44 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.44 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.44 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30915555 | 1.00 | MCOLN3 (0.51) | MCOLN3PPME1PGRRXFP1PTGS2 | |
| Hydrochloric Acid SCHEMBL29739267 | 0.98 | MCOLN3 (0.50) | MCOLN3PPME1PGRRXFP1PTGS2 | |
| SCHEMBL3510232 | 0.85 | PGR (0.52) | PGRNR1H3 | |
| SCHEMBL5441030 | 0.82 | PTGS2 (0.47) | PTGS2 | |
| SCHEMBL1891657 | 0.82 | MCOLN3 (0.49) | MCOLN3PPME1PGRRXFP1ENPP2 | |
| SCHEMBL13911254 | 0.81 | PSIP1 (0.50) | MCOLN3PPME1PGRRXFP1ENPP2 | |
| SCHEMBL689244 | 0.80 | ADAMTS4 (0.55) | MCOLN3PGRPTGS2ACLYKAT6A | |
| SCHEMBL1487652 | 0.80 | TSHR (0.52) | MCOLN3PPME1PGRRXFP1ENPP2 | |
| SCHEMBL791765 | 0.80 | CA2 (0.67) | MCOLN3PGR | |
| SCHEMBL4574069 | 0.80 | KAT6A (0.48) | MCOLN3PGRRXFP1ENPP2ACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 232 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118054087-A | Electrolyte, electrolyte injection method and lithium metal battery | 蜂巢能源科技股份有限公司 | 2024-05-17 | — | — | CN | claimed |
| CN-113130994-A | Electrolyte and electrochemical device comprising same | 深圳市研一新材料有限责任公司 | 2021-07-16 | — | — | CN | claimed |
| US-9870909-B2 | Compositions and methods for mass spectometry | MSTM, LLC | 2018-01-16 | — | — | US | claimed |
| US-12570645-B2 | Uses of p53 x-ray co-crystal structures | PMV PHARMACEUTICALS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260027097-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-20250319063-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2025-10-16 | — | — | US | disclosed |
| US-12419880-B2 | Companion diagnostic tool for mutant p53 reactivating compounds | PMV PHARMACEUTICALS, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20240269126-A1 | COMBINATION THERAPY FOR TREATMENT OF CANCER | PMV PHARMACEUTICALS, INC. | 2024-08-15 | — | — | US | disclosed |
| CN-118054087-B | Electrolyte, electrolyte injection method and lithium metal battery | 蜂巢能源科技股份有限公司 | 2024-07-19 | — | — | CN | disclosed |
| CN-118054087-A | Electrolyte, electrolyte injection method and lithium metal battery | 蜂巢能源科技股份有限公司 | 2024-05-17 | — | — | CN | disclosed |
| US-11938124-B2 | Combination therapy for treatment of cancer | PMV PHARMACEUTICALS, INC. (US) | 2024-03-26 | — | — | US | disclosed |
| US-20030162808-A1 | Acetindine derivatives, their preparation and medicaments containing them | AVENTIS PHARMA S.A. (FR) | 2003-08-28 | — | — | US | disclosed |
| EP-1112251-B1 | AZETIDINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | AVENTIS PHARMA SA (FR) | 2003-05-07 | — | — | EP | disclosed |
| US-6518264-B2 | For treatment/prevention of psychoses, other brain disorders, and cardiovascular disorders | AVENTIS PHARMA S.A. (FR) | 2003-02-11 | — | — | US | disclosed |
| US-20020035102-A1 | Azetidine derivatives, their preparation and medicaments containing them | AVENTIS PHARMA S.A. (FR) | 2002-03-21 | — | — | US | disclosed |
| EP-1112251-A1 | AZETIDINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | Aventis Pharma S.A. (FR) | 2001-07-04 | — | — | EP | disclosed |
| WO-2000015609-A1 | AZETIDINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | AVENTIS PHARMA S.A. (FR) | 2000-03-23 | — | — | WO | disclosed |
| EP-0003259-B1 | N-FORMYLANILIDO AROMATIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PROCESS FOR THE PREPARATION OF THE CORRESPONDING N-PHENYL AROMATIC AMINO COMPOUNDS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1982-03-24 | — | — | EP | disclosed |
| EP-0003259-A1 | N-Formylanilido aromatic compounds, process for their preparation and process for the preparation of the corresponding N-phenyl aromatic amino compounds | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1979-08-08 | — | — | EP | disclosed |
| US-4103009-A | ANTIULCER AGENTS, DIURETICS | NIPPON SHINYAKU CO., LTD. (JP) | 1978-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11938124-B2 | Combination therapy for treatment of cancer | TP53, KRAS, TP53BP1 | MCOLN3 4518/4885PPME1 203/4885PGR 2359/4885 |
| US-20250319063-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | TP53, TP53BP1, KRAS | MCOLN3 4551/4885PPME1 102/4885PGR 2544/4885 |
| US-20260027097-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, BRCA1 | MCOLN3 3413/4885PPME1 353/4885PGR 2158/4885 |
| US-12570645-B2 | Uses of p53 x-ray co-crystal structures | TP53, TP53BP1, ERCC2 | MCOLN3 4316/4885PPME1 270/4885PGR 869/4885 |
| US-20240269126-A1 | COMBINATION THERAPY FOR TREATMENT OF CANCER | TP53, KRAS, TP53BP1 | MCOLN3 4518/4885PPME1 203/4885PGR 2359/4885 |
| US-12419880-B2 | Companion diagnostic tool for mutant p53 reactivating compounds | TP53, TP53BP1, KRAS | MCOLN3 4607/4885PPME1 764/4885PGR 1501/4885 |
| US-20020035102-A1 | Azetidine derivatives, their preparation and medicaments containing them | CYP11B2, AZI2, CYP2C19 | MCOLN3 2339/4885PPME1 3442/4885PGR 449/4885 |
| US-20030162808-A1 | Acetindine derivatives, their preparation and medicaments containing them | ADRA1D, ADRB2, AZI2 | MCOLN3 3297/4885PPME1 4103/4885PGR 2283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.